Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522530 | 0.79 | CYP19A1 (0.41) | PTAFRSLC6A3ADORA3HRH1OPRM1 | |
| SCHEMBL11188706 | 0.79 | PTAFR (0.46) | PTAFRHDAC4HDAC8HDAC5SLC6A2 | |
| SCHEMBL522532 | 0.79 | SLC6A3 (0.44) | PTAFRSLC6A2SLC6A4SLC6A3ADORA3 | |
| SCHEMBL10046465 | 0.78 | OPRM1 (0.44) | OPRM1 | |
| SCHEMBL10046470 | 0.78 | SLC6A3 (0.47) | PTAFRSLC6A2SLC6A4SLC6A3ADORA3 | |
| SCHEMBL10046459 | 0.76 | PTAFR (0.42) | PTAFRSLC6A3ADORA3HRH1OPRM1 | |
| SCHEMBL522353 | 0.75 | PTAFR (0.47) | PTAFRSLC6A3SMARCA2ADORA3OPRM1 | |
| SCHEMBL521671 | 0.73 | PTAFR (0.45) | PTAFROPRM1 | |
| SCHEMBL10046462 | 0.73 | PTAFR (0.44) | PTAFROPRM1 | |
| SCHEMBL10046467 | 0.72 | ALDH1A1 (0.42) | PTAFROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421836-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-29 | — | — | EP | claimed |
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-02 | — | — | US | claimed |
| WO-2010123150-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-28 | — | — | WO | claimed |
| EP-2421836-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2010123150-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | CLIC1, NAT1, NMRAL1 | PTAFR 4849/4885HDAC4 723/4885HDAC8 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.